Dermatomyositis
Conditions
Interventions
In summary, we will use our phototest protocol for patients with DM
1. To determine the minimal erythema dose (MED) for UVB, UVA, and visible light.
2. To determine the clinical aspect of the photoprovoked skin lesions.
3. To determine the time interval between the
Sponsors
Dept of Dermatology/Allergology
University Medical Centre
Heidelberglaan 100, G02.124
3584CX Utrecht
Netherlands
Eligibility
Inclusion criteria
Inclusion criteria: 1. Patients with DM that have been diagnosed according to international accepted guidelines (1-3); 2. The medication that is used by the patients specifically for DM or other related symptoms will be continued during phototesting; 3. The patients should not use corticosteroid creams or sunscreens during phototesting; 4. Patients with DM are invited to participate in this study and are included after signed informed consent is obtained.
Exclusion criteria
Exclusion criteria: Any malignancy for which the patient is treated with cytostatic drugs and/or radiotherapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| In summary, we will determine the initial cutaneous response after UVB provocation of the skin. Specifically we will determine the trafficking of Langerhans cell, leucocytes and lymphocytes and the expression of MMP in skin lesions and compare these with healthy controls, patients with lupus erythematosus and patients with polymorphic light eruption, for which the results have already been obtained. | — |
Contacts
Public ContactCornelus J.G. Sanders
University Medical Center Utrecht (UMCU), Department of Dermatology/Allergology, G02.124, Heidelberglaan 100
Outcome results
None listed